December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

0.8255 +0.0009 (+0.11%)
Streaming Delayed Price Updated: 12:48 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Proposed Public Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
From Xilio Therapeutics, Inc.
Via GlobeNewswire
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.